Recognized Healthcare and Financial Publications Acknowledge Decision Diagnostics’ GenStrip Market Potential
October 22 2013 - 11:36AM
Access Wire
Los Angeles, CA - (October 22, 2013) Decision Diagnostics
Corp. (OTCBB: DECN) the exclusive worldwide sales, service and
regulatory processes agent for the popular Shasta GenStrip[TM], the
unique diabetes monitoring Green Glucose Test Strip, specifically
designed to work with the Johnson & Johnson's (JNJ) LifeScan
Ultra family of glucose testing meters has been the focus of
favorable articles and papers published recently. Today
BioMedReports released an article on the front page of their
website titled “DECN Set to Climb as GenStrip Enters Blood Glucose
Monitoring Market With New Large Shipments.” The article
summarizes DECN’s history and current business. The full
article can be read here:
http://www.biomedreports.com/20131022158602/decn-set-to-climb-as-genstrip-enters-blood-glucose-monitoring-market-with-first-shipments.html
Decision Diagnostics has also been featured in articles in
Forbes, Qmed and Seeking Alpha in the past few months. All of
these articles are available online on their respective
websites.
Keith Berman, Principal Executive Officer of Decision
Diagnostics, commented, “Decision Diagnostics has begun shipping
large box quantities of Shasta GenStrip glucose monitoring test
strips and we are pleased that the disruptive market potential of
the product line is being recognized and written upon by financial
and healthcare publication.”
About BioMedReports
BioMedReports.com is the news portal which
covers Wall Street's biomedical sector and delivers financial and
investment intelligence to a community of highly informed investors
has Healthcare stock news and updates to its calendar database of
Clinical Trials and upcoming FDA approvals & decisions.
Visit http://www.biomedreports.com/.
About Decision Diagnostics:
DECN is a leading provider of prescription and non-prescription
diagnostics, home testing products for the chronically ill and a
premier developer of revolutionary cell phone centric e-health
products and technologies. DECN's FDA cleared Shasta GenStrip™
product was first introduced to the market in late 2012 as a lower
cost (50%) alternative for user/owners of Johnson and Johnson
LifeScan OneTouch® Ultra®, Ultra2® and Ultra Mini® glucose
meters.
Forward-Looking Statements:
This release contains forward-looking statements about our
business or financial condition that reflect our assumptions and
beliefs based on information currently available. We can give no
assurance that the expectations indicated by such forward-looking
statements will be realized. There may be other risks and
circumstances that we are unable to predict. When used in this
release, words such as "believes," "expects," "forecasts,"
"intends," "projects," "plans," "anticipates," "estimates," "will"
and similar expressions are intended to identify forward-looking
statements, although there may be certain statements not
accompanied by such expressions.
For further information about Shasta Genstrip, please visit the
company's web sites: http://www.decisiondiagnostics.com/ or
http://www.shastagenstrip.com/.
GenStrip[TM] test strips are a product of Shasta Technologies,
LLC and are not manufactured, distributed, endorsed, or approved by
nor associated with LifeScan[R], Inc. a Johnson & Johnson[R]
Company, manufacturers and distributors of the OneTouch[R] Ultra[R]
Family of Meters and OneTouch[R] Ultra[R] test strips.
Contact:
Decision Diagnostics Corp.
Keith Berman
(805) 446-2973
info@decisiondiagnostics.com
Decision Diagnostics (CE) (USOTC:DECN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Decision Diagnostics (CE) (USOTC:DECN)
Historical Stock Chart
From Jul 2023 to Jul 2024